Revenue qualityDanger
매출 흑자인데 영업CF 적자 (OCF/매출 -515%). 통계적 정황 신호이며 회계부정 단정이 아닙니다.
Oncocross
A382150 · KOSDAQ₩2,945+7.88%
2026-08-03 closeLoading chart…
Close
AI Insight
Why these signals fired — only backtest-proven edge, told honestly
Strong-buy signal — the real recordrecord · not a prediction
Not this one stock, but every strong-buy pick we actually published (Korea market). When this stock flashes the signal, it is treated by the same rule.(as of 2026-08-03)
Last 30 sessions
648 picks
Next-day win rate
49.2%
Avg next-day
-0.17%
vs market
+0.72%p
Beat the market on 62.1% of picks (each pick vs its own day’s market average).
Recent publish days (next-day win rate)
07-31 0%07-30 66.7%07-29 0%07-28 45%07-27 20%07-25 36.4%07-21 55.6%07-20 53.8%07-16 53.3%07-15 50%07-14 71.4%07-13 31.2%
This stock has not flashed this signal recently — the record above is the signal’s own, not this stock’s.
Entry is the latest close at publish time; next-day is the following close. “Market” is the equal-weighted average of every stock in the same market that day; delisted names are excluded from both. Fees, taxes and slippage are not included. An observed record over a short window, not a pre-registered backtest. Not investment advice.
Financial safety
Reference indicatorAs of 2024Safe zoneFinancial-metric reference signal
Altman Z'' zoneZ'' 6.68
Distress
Grey
Safe
- Altman Z''
- 6.68
- Beneish M-Score
- 6.16
- Sloan accrual
- -4.25%
Statistical manipulation-risk signal
부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.
Factual information, not investment advice.
Earnings quality · Piotroski F-Score
4/9Moderate
Piotroski measures year-over-year financial improvement, not absolute quality.
Financial improvement score4/9
Profitability
- Positive ROANot passed
- Positive OCFNot passed
- Improving ΔROANot passed
- Accruals (OCF > net income)Pass
Leverage & liquidity
- Lower debtNot passed
- Higher current ratioNot passed
- No new sharesPass
Efficiency
- Higher gross marginPass
- Higher asset turnoverPass
Calculation note: F7(신주)은 equity/asset 유지로 근사
Already-stable companies may score lower when year-over-year improvement is limited.
Factual information, not investment advice.
Forensic signals
Anomaly and structural signals observed in the financial statements.
Factual information, not investment advice.
Risk sensitivity — adverse assumptions
Metric changes under stated assumptions; not a forecast or investment advice.
Base metrics
- Operating margin
- -649.6%
- Interest coverage
- -370.6x
- Return on equity (ROE)
- -31.7%
Operating margin −5pp
Operating lossInterest coverageBase -370.6x adverse case -373.5x
Return on equity (ROE)Base -31.7% adverse case -34.4%
Revenue −15%
Interest coverage riskInterest coverageBase -370.6x adverse case -315x
Return on equity (ROE)Base -31.7% adverse case -29%
Interest rate +2pp
Interest coverage riskInterest coverageBase -370.6x adverse case -114.9x
Return on equity (ROE)Base -31.7% adverse case -34.3%
Interest coverage limit
Already below the limit by 651.3ppInterest coverage limit at an operating margin of 1.8%
Interest expense coverage threshold
Financials at a glance
Oncocross's latest results and balance sheet. The bars track the last three periods.
Who held it · filings
Filed recordA historical record from curated-guru 13F filings and DART 5%+ major-holding disclosures.
US 13F는 분기 공시이며 최대 45일 뒤 제출될 수 있습니다.
5%+ major-holding disclosures
- 김이랑34.67%2026-06-12 · 증감 +0.09%p
- 인터베스트10.15%2024-12-18 · 증감 +10.15%p
- 이현자산운용6.91%2026-07-10 · 증감 -0.50%p
Other stocks held by the same investors
A filing-based shared-holder record, not investment advice.
- 파이버프로KRA368770 →
Shared holders: 인터베스트
- 아이지넷KRA462980 →
Shared holders: 인터베스트
- 토모큐브KRA475960 →
Shared holders: 인터베스트
Recent filings
Oncocross's latest filings on Korea's DART. Open a headline for a reference summary and the original.
Source: DART (Korea electronic disclosure)
Like these rules? Run them automatically.
Quantus turns rules like these into backtests and automated trading — same team, free to start.
Quantus Signal · live data · not investment advice · Privacy Policy